Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
63.2
USD
+2.88%
+1.27%
+22.15%
Presentation Operator MessageOperator (Operator)Good day, ladies and gentlemen and welcome to ...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
LivaNova's Q1 Adjusted Earnings, Revenue Rise, Tops Street View; Raises 2024 Guidance
May. 01
MT
Transcript : LivaNova PLC, Q1 2024 Earnings Call, May 01, 2024
May. 01
Earnings Flash (LIVN) LIVANOVA Reports Q1 Revenue $294.9M, vs. Street Est of $278.2M
May. 01
MT
Earnings Flash (LIVN) LIVANOVA Posts Q1 EPS $0.73, vs. Street Est of $0.49
May. 01
MT
LivaNova PLC Provides Earnings Guidance for the Full-Year 2024
May. 01
CI
LivaNova PLC Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 01
CI
LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
Apr. 30
CI
Sector Update: Health Care Stocks Ease Late Afternoon
Mar. 20
MT
Sector Update: Health Care Stocks Down Wednesday Afternoon
Mar. 20
MT
LivaNova Says Sleep Apnea Study Likely to Meet Primary Efficacy Endpoint; Shares Jump
Mar. 20
MT
LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
Mar. 20
CI
Transcript : LivaNova PLC Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM
Mar. 12
LivaNova Proposes $300 Million Private Placement of Notes
Mar. 04
MT
Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating
Feb. 27
MT
Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating
Feb. 26
MT
Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating
Feb. 22
MT
Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating
Feb. 22
MT
Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating
Feb. 22
MT
Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating
Feb. 21
MT
Transcript : LivaNova PLC, Q4 2023 Earnings Call, Feb 21, 2024
Feb. 21
LivaNova's Q4 Adjusted Earnings, Revenue Increase; Sets 2024 Guidance
Feb. 21
MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 Revenue $310.1M, vs. Street Est of $287.7M
Feb. 21
MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 EPS $0.87, vs. Street Est of $0.77
Feb. 21
MT
LivaNova PLC Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 21
CI
Livanova plc Provides Earnings Guidance for the Full-Year 2024
Feb. 21
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Companyâs next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
More about the company
Last Close Price
63.2
USD
Average target price
69.2
USD
Spread / Average Target
+9.49%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**